Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience

被引:108
作者
Vandone, A. M. [1 ]
Donadio, M. [1 ]
Mozzati, M. [2 ]
Ardine, M. [1 ]
Polimeni, M. A. [1 ]
Beatrice, S. [1 ]
Ciuffreda, L. [1 ]
Scoletta, M. [2 ]
机构
[1] San Giovanni Battista Molinette Hosp, Dept Med Oncol & Hematol, COES, Subalpine OncoHematol Canc Ctr, I-10126 Turin, Italy
[2] San Giovanni Battista Molinette Hosp, Dept Oral Surg, I-10126 Turin, Italy
关键词
bisphosphonate; bone metastases; osteonecrosis of the jaw; solid tumor; SKELETAL COMPLICATIONS; MULTIPLE-MYELOMA; ZOLEDRONIC ACID; CANCER-PATIENTS; BREAST-CANCER; BONE METASTASES; SOLID TUMORS; RISK-FACTORS; DOUBLE-BLIND; PAMIDRONATE;
D O I
10.1093/annonc/mdr039
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Osteonecrosis of the jaw (ONJ) is associated with bisphosphonate (BP) therapy and invasive dental care. An Interdisciplinary Care Group (ICG) was created to evaluate dental risk factors and the efficacy of a preventive restorative dental care in the reduction of ONJ risk. Patients and methods: This prospective single-center study included patients with bone metastases from solid tumors. Patients who received at least one BP infusion between October 2005 and 31 August 2009 underwent one or more ICG evaluation and regular dental examinations. We also retrospectively evaluated patients with bone metastases from solid tumors who did not undergo dental preventive measures. Results: Of 269 patients, 211 had received at least one infusion of BP therapy: 62% were BP naive and 38% had previous BP exposure. Of these 211 patients followed for 47 months, 6 patients developed ONJ (2.8%). Of 200 patients included in the retrospective analysis, 11 patients developed ONJ (5.5%). Conclusions: In comparison with published ONJ rates and those extrapolated from the retrospective analysis, the observed ONJ rate in the prospective group was lower, suggesting that implementation of a preventive dental program may reduce the risk of ONJ in metastatic patients treated with i.v. BP therapy.
引用
收藏
页码:193 / U18
页数:8
相关论文
共 31 条
[1]
Guidance on the use of bisphosphonates in solid tumours:: recommendations of an international expert panel [J].
Aapro, M. ;
Abrahamsson, P. A. ;
Body, J. J. ;
Coleman, R. E. ;
Colomer, R. ;
Costa, L. ;
Crino, L. ;
Dirix, L. ;
Gnant, M. ;
Gralow, J. ;
Hadji, P. ;
Hortobagyi, G. N. ;
Jonat, W. ;
Lipton, A. ;
Monnier, A. ;
Paterson, A. H. G. ;
Rizzoli, R. ;
Saad, F. ;
Thuerlimann, B. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :420-432
[2]
Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].
Badros, A ;
Weikel, D ;
Salama, A ;
Goloubeva, O ;
Schneider, A ;
Rapoport, A ;
Fenton, R ;
Gahres, N ;
Sausville, E ;
Ord, R ;
Meiller, T .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952
[3]
Bagan Jose, 2007, Med Oral Patol Oral Cir Bucal, V12, pE336
[4]
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].
Bamias, A ;
Kastritis, E ;
Bamia, C ;
Moulopoulos, LA ;
Melakopoulos, L ;
Bozas, G ;
Koutsoukou, V ;
Gika, D ;
Anagnostopoulos, A ;
Papadimitriou, C ;
Terpos, E ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587
[5]
Osteonecrosis of the jaw (ONJ) in patients with prostate (PC) or breast (BC) cancer treated with bisphosphonates: Study of the effect of the application of preventive measures [J].
Bamias, A. ;
Kastritis, E. ;
Melakopoulos, I. ;
Gika, D. ;
Roussou, M. ;
Migkou, M. ;
Eleftherakis-Papaiakovou, E. ;
Dimopoulos, M. A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[6]
What is Piezosurgery®?: Two-years experience in craniomaxillofacial surgery [J].
Beziat, J. -L. ;
Vercellotti, T. ;
Gleizal, A. .
REVUE DE STOMATOLOGIE DE CHIRURGIE MAXILLO-FACIALE ET DE CHIRURGIE ORALE, 2007, 108 (02) :101-107
[7]
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].
Body, JJ ;
Diel, IJ ;
Lichinitser, MR ;
Kreuser, ED ;
Dornoff, W ;
Gorbunova, VA ;
Budde, M ;
Bergström, B .
ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405
[8]
Durie BGM, 2005, NEW ENGL J MED, V353, P99
[9]
Osteonecrosis of the jaw related to bevacizumab [J].
Estilo, Cherry L. ;
Fornier, Monica ;
Farooki, Azeez ;
Carlson, Diane ;
Bohle, George, III ;
Huryn, Joseph M. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :4037-4038
[10]
Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]